Key facts
- This page summarizes Atai Beckley N.V.'s Form 4 filing for IntelGenx Technologies Corp..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 May 2024, 16:05.
Atai Beckley N.V. - 19 Apr 2024 Form 4 Insider Report for IntelGenx Technologies Corp.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 19 Apr 2024
- Net transaction value
- +$1,000,000
- SEC form
- 4
- Accepted by SEC
- 03 May 2024, 16:05:22 UTC
- Prior SEC filing
- 12 Mar 2024
- Next SEC filing
- 27 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- ATAI Life Sciences N.V., By: /s/ Florian Brand, Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Atai Beckley N.V. filed Form 4 for IntelGenx Technologies Corp. on 03 May 2024.
Change
- Previous filing in this sequence was filed on 12 Mar 2024.
- Current net transaction value: +$1,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IGXT
transaction
Derivative
Convertible Notes
Other
- Transaction value
- $1,000,000
- Shares
- Change %
- Price
- Shares after
- $10,500,000
- Date
- 19 Apr 2024
- Ownership
- By ATAI Life Sciences AG
- Underlying class
- Common Stock
- Underlying amount
- 5,405,405
- Exercise price
- $0.1850
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable.
Footnote F2
Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.